Report Highlights

The United States' Role in the Global Narcolepsy Therapeutics Supply Chain

The United States is the single largest value-capture node for narcolepsy therapeutics, absorbing a dominant share of global sodium oxybate and wakefulness-promoting agent revenue. Domestic production of branded oxybate is limited, with Jazz Pharmaceuticals and Avadel Pharmaceuticals relying on a small group of qualified manufacturing partners, so the country captures most value at prescribing, distribution and reimbursement rather than synthesis. For generic modafinil and armodafinil, the United States is a net importer of active pharmaceutical ingredients, sourced predominantly from Indian and Chinese manufacturers before finished-dose production in New Jersey, Pennsylvania and Puerto Rico.

Sodium oxybate is classified as a Schedule III controlled substance, so supply is governed by DEA annual production quotas and closed-loop distribution through certified specialty pharmacies. That regulatory architecture concentrates supply risk in a narrow set of nodes, leaving the system exposed to a single REMS compliance failure or quota shortfall. Non-controlled alternatives, including Harmony Biosciences' pitolisant and Axsome Therapeutics' solriamfetol, diversify the therapeutic supply base and reduce dependence on oxybate logistics. Vulnerability remains in generic API imports, where a tariff shock would reach patients within months.

Growth Drivers for U.S. Narcolepsy Trade and Production

Once-nightly oxybate formulations are reshaping production demand. Avadel Pharmaceuticals' Lumryz, approved by the FDA in 2023, converts patients from twice-nightly dosing and requires manufacturing and packaging lines distinct from legacy liquid products. Jazz Pharmaceuticals' Xywav, the low-sodium oxybate approved for narcolepsy in 2020, has created a parallel sodium-restricted production stream, adding compliance-driven capacity requirements. Together, these reformulations expand the volume of controlled-substance inputs flowing through domestic fill-finish sites.

Orexin receptor agonists represent the next production wave. Takeda's oveporexton and Alkermes' alixorexton are advancing through late-stage development for narcolepsy type 1, and commercial launch would shift sourcing toward novel small-molecule active ingredients synthesised by contract development and manufacturing organisations, many located in Europe and Asia. Import substitution is also emerging, as manufacturers respond to the Section 232 pharmaceutical investigation by evaluating domestic API capacity for generic wakefulness agents.

Supply Chain Risks and Trade Barriers

Active ingredient dependence is the sharpest exposure. Generic modafinil and armodafinil API supply is concentrated among a limited number of Indian and Chinese producers, and a batch-level regulatory action at a single site can remove a significant share of U.S. generic volume. Sodium oxybate faces a parallel constraint: a DEA quota shortfall for a Schedule III input restricts output regardless of manufacturing capacity, and quota adjustments operate on annual cycles that prevent rapid response to demand spikes.

Trade and logistics barriers add cost. Section 301 tariffs on Chinese-origin goods apply to many pharmaceutical intermediates, and Section 232 outcomes for finished products remain open. Controlled-substance logistics require chain-of-custody documentation, DEA registration and REMS verification, which lengthens lead times for specialty distributors compared with ordinary pharmaceuticals. Currency exposure is limited because contracts are largely dollar-denominated, but euro-denominated CDMO agreements for orexin compounds expose margins to exchange rate movement.

Trade and Investment Opportunities in the United States

Domestic API capacity for generic wakefulness agents is an underserved opportunity. Modafinil and armodafinil account for a large volume of U.S. generic prescriptions, yet domestic active ingredient output is marginal, creating room for cost-competitive plants in established pharmaceutical hubs such as New Jersey and North Carolina. Contract manufacturers that secure DEA registration for controlled-substance handling can capture share from importers exposed to tariff and inspection risk.

Inbound foreign direct investment should target orexin agonist fill-finish and sterile packaging capacity ahead of expected launch volumes. Specialty distribution hubs in Texas and Pennsylvania offer logistics proximity to major payer markets, and controlled-substance warehousing licences create entry barriers that reward early investors. Investors who secure sites before 2028 capture the capacity gap that orexin launches will open.

Market at a Glance

Leading Market Participants

• Jazz Pharmaceuticals
• Harmony Biosciences
• Avadel Pharmaceuticals
• Axsome Therapeutics
• Teva Pharmaceuticals
• Viatris
• Alkermes
• Takeda Pharmaceutical
• Centessa Pharmaceuticals
• Sun Pharmaceutical Industries

Regulatory and Trade Policy Environment

Narcolepsy therapeutics are governed by the FDA, which grants orphan drug designation under the Orphan Drug Act and seven years of market exclusivity for approved indications. Sodium oxybate's Schedule III status requires DEA production quotas, handler registration and REMS-based dispensing. Most finished pharmaceutical imports enter at low or zero Harmonized Tariff Schedule rates, but the Section 232 pharmaceutical investigation and Section 301 measures on Chinese-origin inputs create policy uncertainty for generic supply chains.

Pricing policy shapes trade economics. The Inflation Reduction Act's Medicare drug price negotiation program targets high-expenditure drugs, but orphan-designated indications receive extended exclusion, which preserves launch economics for narcolepsy products. Trade frameworks, including USMCA rules of origin for North American inputs and arrangements with the European Union and Japan, determine the origin treatment applied to imported finished products and active ingredients.

U.S. Narcolepsy Supply Chain Outlook to 2032

The supply chain will shift from oxybate-centred controlled-substance logistics toward a mixed portfolio of oxybates, non-controlled wakefulness agents and orexin agonists. Orexin agonists are small molecules, so their active ingredient synthesis is more amenable to continuous manufacturing and multi-site contracting. As launches proceed, U.S. imports of novel API intermediates will rise from European and Asian CDMOs, reshaping trade flows toward higher-value specialty inputs.

Comparative advantage will move toward producers that combine DEA-registered controlled-substance handling with continuous-flow chemistry. Domestic fill-finish capacity will expand as payers and distributors reward shorter lead times, while generic modafinil API will remain import-dependent until tariff measures justify onshoring. The 2032 supply landscape will reward operators that qualify across both oxybate and orexin product lines.